Large or small, your ‘call center’ is essential to a good first impression.
Errors related to bladder cancer site and symptom codes could lead to take backs.
Several strategies are available, each with their own pros and cons.
Both the efficacy and safety of abiraterone acetate (ZYTIGA) treatment for metastatic castrate-resistant prostate cancer (mCRPC) appear to differ depending on race, according to results of Abi Race, a prospective, multicenter trial presented at the American Society of Clinical Oncology annual meeting in Chicago.
Median overall survival for African-American men with advanced prostate cancer who are treated with docetaxel (Taxotere) is similar to that of Caucasian men, according to an analysis of pooled data from nine randomized phase III clinical trials.
"Two provocative studies reported at the 2018 ASCO annual meeting provide additional insight into prostate cancer racial disparities in a different group of patients, namely men with advanced prostate cancer who participated in a variety of clinical trials," writes Leonard G. Gomella, MD.
"Many people, including many practicing urologists, are unaware that over the course of the past 40 years, the Urology Care Foundation has supported more than 750 young scientists... with nearly $30 million in funding," writes Brian R. Stork, MD.
Patients with advanced non-clear cell renal cell carcinoma have a high prevalence of germline mutations, including some that could be used to guide therapy.
The finding suggests that, in the setting of a CD117-positive renal tumor biopsy, this modality could reduce patient morbidity and health care costs by avoiding the need for resection in benign cases.
Failure to provide an interpreter incurs legal and regulatory risk.